8 active not recruiting. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Active not recruiting 8 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. Avacopan - Vasculitis | Phase 3 | Active not recruiting | Amgen | 19 | 2024-10-22 | 2026-07-20 |
| TocilizuMab discontinuAtion in GIant Cell Arteritis Tocilizumab treatment, questionnaires, Blood samples - Giant Cell Arteritis | Phase 3 | Active not recruiting | Centre Hospitalier Universitaire Dijon | 120 | 2024-05-13 | 2026-05-04 |
| Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Depemokimab, Mepolizumab, Placebo matching mepolizumab - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Active not recruiting | GlaxoSmithKline | 163 | 2022-07-14 | 2026-07-08 |
| Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement Tocilizumab, Placebo - Giant Cell Arteritis, Neurovascular Disorder | Phase 3 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 66 | 2021-09-24 | 2025-06-25 |
| A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) Upadacitinib, Placebo for Upadacitinib, Prednisolone - Takayasu Arteritis (TAK) | Phase 3 | Active not recruiting | AbbVie | 56 | 2020-02-04 | 2026-02-18 |
| MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial Prednisone treatment, Tocilizumab treatment, Methotrexate treatment - Giant Cell Arteritis | Phase 3 | Active not recruiting | Centre Hospitalier Universitaire Dijon | 230 | 2020-01-27 | 2026-04-24 |
| Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. Benralizumab, Mepolizumab, Placebo to Mepolizumab - Eosinophilic Granulomatous Vasculitis | Phase 3 | Active not recruiting | AstraZeneca | 140 | 2019-10-29 | 2026-08-12 |
| Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease Discontinuation (or not initiation) of Immunosuppressive Therapy, Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl® - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, End Stage Renal Disease | Phase 3 | Active not recruiting | Centre Hospitalier Departemental Vendee | 136 | 2018-02-02 | 2026-03-20 |
Giant Cell Arteritis (3) · Churg-Strauss Syndrome (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Cerebrovascular Disorders (1) · Kidney Failure, Chronic (1) · Takayasu Arteritis (1) · Vascular Diseases (1)
Cardiovascular Diseases (8) · Skin Diseases (7) · Skin Diseases, Vascular (7) · Skin and Connective Tissue Diseases (7) · Vascular Diseases (7) · Autoimmune Diseases (6) · Immune System Diseases (6) · Arteritis (4) · Autoimmune Diseases of the Nervous System (3) · Brain Diseases (3) · Central Nervous System Diseases (3) · Nervous System Diseases (3) · Systemic Vasculitis (3) · Vasculitis, Central Nervous System (3)
Blood Specimen Collection (2) · Surveys and Questionnaires (2) · mepolizumab (2) · Immunosuppression Therapy (1) · Maintenance (1) · Prednisolone (1) · Prednisone (1) · avacopan (1) · benralizumab (1) · tocilizumab (1) · upadacitinib (1)
Centre Hospitalier Universitaire Dijon (2) · AbbVie (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Centre Hospitalier Departemental Vendee (1) · GlaxoSmithKline (1)
France (7) · Canada (3) · Japan (3) · United States (3) · Argentina (2) · Belgium (2) · Brazil (2) · China (2) · Germany (2) · Israel (2) · Italy (2) · Poland (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2)
PMID 33164993, PMID 36963127, PMID 38393328, PMID 40977418, PMID 41067765
2023 (2), 2019 (1)